Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

enthesitis-related juvenile idiopathic arthritis (ERA) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

enthesitis-related juvenile idiopathic arthritis

MONDO:0019437

Also known as:ERAenthesitis-related JIAenthesitis related arthritis, juvenile

Find Clinical TrialsTrials

Overview

Enthesitis-related juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis that is characterized by both arthritis and inflammation of an enthesitis site (the point at which a ligament, tendon, or joint capsule attaches to the bone). Signs and symptoms generally develop in late childhood or early adolescence and include pain, tenderness, and swelling in joints and at the enthesis. The knee and the back of the ankle (at the Achilles tendon) are the most commonly affected parts of the body. The underlying cause of enthesitis-related juvenile idiopathic arthritis is currently unknown (idiopathic). It is very rare for more than one member of a family to have juvenile arthritis; however, research suggests that having a family member with juvenile arthritis or any autoimmune disease may increase the risk of having juvenile arthritis, in general. Treatment usually involves different types of medications to help manage symptoms and/or physical therapy.

Treatments1 FDA approved

Clinical Trials7 registered · 3 recruiting

Diagnosis

Biomarker and diagnostic research for enthesitis-related juvenile idiopathic arthritis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for enthesitis-related juvenile idiopathic arthritis, including SECUKINUMAB (COSENTYX, approved 2023).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Prognosis

Estimated prevalence: 1-9 in 100,000 (Uncommon).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

7 clinical trials registered, 3 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 3 PHASE3. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT03773965](https://clinicaltrials.gov/study/NCT03773965)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 10:51 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:85438

GARD

Genetic and Rare Diseases Info Center

GARD:10969

Questions for Your Care Team

→What are the benefits and potential side effects of COSENTYX for managing enthesitis-related juvenile idiopathic arthritis?
→Are any of the 7 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Disease patterns and progression	29	33%
Research summaries	18	21%
Clinical study results	14	16%
Testing and diagnosis research	11	13%
Laboratory research	7	8%
Patient case studies	6	7%
Other research	2	2%

Kisho

enthesitis-related juvenile idiopathic arthritis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Clinical Characteristics of Enthesitis-Related Arthritis and Outcomes of Treatment with Salazosulfapyridine.

enthesitis-related juvenile idiopathic arthritis

Overview

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

Clinical Characteristics of Enthesitis-Related Arthritis and Outcomes of Treatment with Salazosulfapyridine.